QRxPharma’s Dual Opioid portfolio includes three complementary products: Q8003, an immediate-release oral capsule for acute pain; Q8011, a controlled-release oral tablet (with abuse deterrent and tamper resistant features) for chronic pain; Q8012, an intravenous formulation for moderate to severe pain secondary to hospital based procedures.

1 Moxduo is the tradename QRxPharma has registered for Q8003. This proprietary name is subject to FDA review in connection with the New Drug Application file on August 2011. Q8003 is not approved for sale by FDA or any other regulatory authority in any country. Because Q8003 is not approved, no conclusions about its safety or efficacy can be drawn from clinical trial data presented on this website.